Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-02 phase 3 trial of olomorasib plus standard immunotherapy in KRAS G12C-mutated non-small cell lung cancer
MOH_2025-03-12_013949Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olomorasib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Eli Lilly and Company. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-03-12_013949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-12_013949.